Effect of DMARDs on the immunogenicity of vaccines.

Yannick van Sleen, Kornelis S M van der Geest, Anke L W Huckriede, Debbie van Baarle, Elisabeth Brouwer

Nature reviews. Rheumatology 2023 Sep

filter terms:

Vaccines are important for protecting individuals at increased risk of severe infections, including patients undergoing DMARD therapy. However, DMARD therapy can also compromise the immune system, leading to impaired responses to vaccination. This Review focuses on the impact of DMARDs on influenza and SARS-CoV-2 vaccinations, as such vaccines have been investigated most thoroughly. Various data suggest that B cell depletion therapy, mycophenolate mofetil, cyclophosphamide, azathioprine and abatacept substantially reduce the immunogenicity of these vaccines. However, the effects of glucocorticoids, methotrexate, TNF inhibitors and JAK inhibitors on vaccine responses remain unclear and could depend on the dosage and type of vaccination. Vaccination is aimed at initiating robust humoral and cellular vaccine responses, which requires efficient interactions between antigen-presenting cells, T cells and B cells. DMARDs impair these cells in different ways and to different degrees, such as the prevention of antigen-presenting cell maturation, alteration of T cell differentiation and selective inhibition of B cell subsets, thus inhibiting processes that are necessary for an effective vaccine response. Innovative modified vaccination strategies are needed to improve vaccination responses in patients undergoing DMARD therapy and to protect these patients from the severe outcomes of infectious diseases. © 2023. Springer Nature Limited.

Citation

Yannick van Sleen, Kornelis S M van der Geest, Anke L W Huckriede, Debbie van Baarle, Elisabeth Brouwer. Effect of DMARDs on the immunogenicity of vaccines. Nature reviews. Rheumatology. 2023 Sep;19(9):560-575